Positive impact of Platelet-rich plasma and Platelet-rich fibrin on viability, migration and proliferation of osteoblasts and fibroblasts treated with zoledronic acid.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
05 06 2019
Historique:
received: 14 11 2018
accepted: 30 04 2019
entrez: 6 6 2019
pubmed: 6 6 2019
medline: 30 10 2020
Statut: epublish

Résumé

Bisphosphonates are frequently used for the antiresorptive treatment in bone metastasis diseases or for osteoporosis. A side effect of this therapy is osteonecrosis of the jaw. This inhibits osteoclast function, but osteoblasts and fibroblasts are also negatively affected in terms of impaired proliferation. Additive local treatment with platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) promotes adhesion, proliferation and migration of cells due to high concentrations of growth factors like PDGF, TGF and IGF. The aim of the study was to investigate the effect of PRP or PRF on proliferation, migration and viability of osteoblasts and oral fibroblasts, treated with zoledronic acid (ZA). ZA treated fibroblasts and osteoblasts were exposed to PRP/PRF. Cell proliferation, migration and viability were measured using the real-time cell-analyzer assay (RTCA), the scratch assay and the MTT assay. There was a significant increase in closure of the scratch area by PRP/PRF treated osteoblasts (PRP = 40.6%, PRF = 100.0%, NC = 0.0%) as well as fibroblasts (PRP = 100.0%, PRF = 100.0%, NC = 12.7%) in comparison to the group of negative control (all p ≤ 0.05). Furthermore, the negative effect of ZA on cell migration was generally reduced in both cell lines using PRP/PRF. The viability and proliferation of cells decreased after exposure to ZA, whereas we observed an enhancement of cell viability within 24 hours by application of PRP/PRF in ZA treated cells. The negative effect of ZA on cell proliferation was especially reduced when using PRF. The use of PRF/PRP improves the behavior of ZA-treated cells, but PRF appears to have an advantage in comparison to PRP. This study demonstrates that treatment with PRF/PRP may have positive effects in the therapy of Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ).

Identifiants

pubmed: 31165745
doi: 10.1038/s41598-019-43798-z
pii: 10.1038/s41598-019-43798-z
pmc: PMC6549154
doi:

Substances chimiques

Diphosphonates 0
Intercellular Signaling Peptides and Proteins 0
Platelet-Derived Growth Factor 0
Zoledronic Acid 6XC1PAD3KF

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

8310

Références

Cells. 2018 Sep 19;7(9):
pubmed: 30235859
J Bone Miner Res. 2008 Nov;23(11):1712-21
pubmed: 18597631
Curr Pharm Biotechnol. 2012 Jun;13(7):1145-52
pubmed: 21740377
Transfusion. 2017 Apr;57(4):1058-1065
pubmed: 28182293
Biomaterials. 2005 May;26(15):2575-84
pubmed: 15585260
Int J Oral Maxillofac Surg. 2005 Jun;34(4):420-4
pubmed: 16053853
J Craniofac Surg. 2005 Mar;16(2):280-7
pubmed: 15750426
J Periodontol. 2008 Apr;79(4):714-20
pubmed: 18380566
Orthop Clin North Am. 1990 Jan;21(1):199-209
pubmed: 2296458
Arch Oral Biol. 2011 May;56(5):491-8
pubmed: 21146154
Exp Ther Med. 2018 Apr;15(4):4029-4038
pubmed: 29556269
Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):9656-61
pubmed: 12118119
Blood Transfus. 2008 Jan;6(1):12-7
pubmed: 18661919
Head Face Med. 2010 Jul 08;6:11
pubmed: 20615236
Support Care Cancer. 2007 Feb;15(2):197-202
pubmed: 16941133
Transfusion. 2009 Apr;49(4):771-8
pubmed: 19170984
Clin Oral Investig. 2016 Dec;20(9):2353-2360
pubmed: 26809431
Eur J Oral Implantol. 2010 Summer;3(2):121-34
pubmed: 20623037
Bone Res. 2016 Dec 13;4:16036
pubmed: 28018706
Biomaterials. 2004 Oct;25(23):5387-93
pubmed: 15130723
J Cell Biochem. 2004 Nov 15;93(5):990-8
pubmed: 15389881
Arch Biochem Biophys. 2011 Mar 15;507(2):248-53
pubmed: 21167123
J Craniomaxillofac Surg. 2019 Feb;47(2):365-372
pubmed: 30578012
Cancers (Basel). 2019 Feb 11;11(2):
pubmed: 30754651
BMC Oral Health. 2017 Jun 2;17(1):91
pubmed: 28578703
Oral Dis. 2011 Mar;17(2):194-9
pubmed: 20796232
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Nov;108(5):707-13
pubmed: 19836723
Br J Cancer. 2010 Mar 30;102(7):1099-105
pubmed: 20234364
Clin Ther. 2003 Nov;25(11):2669-708
pubmed: 14693298
J Craniomaxillofac Surg. 2002 Apr;30(2):97-102
pubmed: 12069512
Clin Oral Implants Res. 2008 Jun;19(6):539-45
pubmed: 18422984
J Biomed Mater Res A. 2010 Oct;95(1):327-32
pubmed: 20623670
Eur J Med Chem. 2018 Oct 5;158:184-200
pubmed: 30216851
J Transl Med. 2016 Mar 15;14:73
pubmed: 26980293
J Am Dent Assoc. 2007 Jul;138(7):971-7
pubmed: 17606496
Int J Mol Sci. 2017 Feb 04;18(2):
pubmed: 28165420
Tissue Eng Part C Methods. 2012 Mar;18(3):176-85
pubmed: 21951067
Stem Cell Res Ther. 2015 Sep 15;6:173
pubmed: 26373929
Am J Sports Med. 2015 Dec;43(12):2898-906
pubmed: 26460099
Acta Odontol Scand. 2016 Oct;74(7):550-557
pubmed: 27546224
Support Care Cancer. 2010 Apr;18(4):449-60
pubmed: 19609572
Tissue Eng Part A. 2011 Nov;17(21-22):2723-37
pubmed: 21679135
Oral Oncol. 2008 Sep;44(9):857-69
pubmed: 18282788
Wound Repair Regen. 2008 May-Jun;16(3):356-63
pubmed: 18282265
Platelets. 2018 Jan;29(1):48-55
pubmed: 28351189
BMC Musculoskelet Disord. 2015 Nov 16;16:355
pubmed: 26572124
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Sep;108(3):341-52
pubmed: 19589702
J Oral Maxillofac Surg. 2007 Mar;65(3):369-76
pubmed: 17307580
J Orthop Sci. 2016 Sep;21(5):683-9
pubmed: 27503185
Tissue Eng. 2004 May-Jun;10(5-6):955-64
pubmed: 15265313
Injury. 2011 Aug;42(8):833-7
pubmed: 21529804
Clin Oral Investig. 2018 Sep;22(7):2527-2534
pubmed: 29388023
J Clin Pharmacol. 2002 Nov;42(11):1228-36
pubmed: 12412821
J Periodontol. 2007 Oct;78(10):1985-91
pubmed: 18062120
J Carcinog. 2011 Jan 15;10:2
pubmed: 21297922
Knee Surg Sports Traumatol Arthrosc. 2012 Oct;20(10):2082-91
pubmed: 22203046
Scand J Urol Nephrol. 2009;43(6):442-4
pubmed: 19903091
Clin Oral Implants Res. 2012 Sep;23(9):1104-11
pubmed: 22092788
J Biomed Mater Res A. 2004 Oct 1;71(1):162-71
pubmed: 15368266
Tissue Eng Part B Rev. 2014 Aug;20(4):267-76
pubmed: 24004354
J Clin Oncol. 2005 Dec 1;23(34):8580-7
pubmed: 16314620
Clin Exp Rheumatol. 2010 Nov-Dec;28(6):873-9
pubmed: 21205463

Auteurs

Daniel Steller (D)

University Hospital Schleswig-Holstein, Department of Maxillofacial Surgery, Ratzeburger Allee 160, 23562, Luebeck, Germany. Daniel.steller@uksh.de.

Nele Herbst (N)

University Hospital Schleswig-Holstein, Department of Maxillofacial Surgery, Ratzeburger Allee 160, 23562, Luebeck, Germany.

Ralph Pries (R)

University Hospital Schleswig-Holstein, Department of Otolaryngology-Head and Neck Surgery, Ratzeburger Allee 160, 23562, Luebeck, Germany.

David Juhl (D)

University Hospital Schleswig-Holstein, Department of Transfusion Medicine, Ratzeburger Allee 160, 23562, Luebeck, Germany.

Samer G Hakim (SG)

University Hospital Schleswig-Holstein, Department of Maxillofacial Surgery, Ratzeburger Allee 160, 23562, Luebeck, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH